Company intelligence / Profile preview
ImmunoScape
Singapore, Singaporeimmunoscape.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
ImmunoScape has not yet entered clinical trials but has developed a robust preclinical pipeline of novel TCR-based therapeutics targeting solid tumors. The company’s technology enables rapid identification of safe and efficacious TCRs with potential for multiple therapeutic modalities. No published clinical results as of May 2025.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- TCR-T cell therapies (T cell receptor-based therapeutics)Bispecific immune cell engagersImmune profiling services
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Experimental Drug Development Centre (EDDC), Singapore/A*STAR – joint development of off-the-shelf bispecific molecules targeting solid tumorsMiNK Therapeutics – collaboration to accelerate novel TCR identification for use in iNKT cells and bispecific engagers against solid tumorsAcademic collaborations with University of Tokyo Edge Capital Partners/UTEC
Beyond the preview
Go deeper on ImmunoScape.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmunoScape.